01Rules Have a Hierarchy ── the Upper Binds the Lower

The rules a material must obey are not a single flat list. They form a hierarchy with an up and a down. Without this map first, you cannot decide what to make the AI prioritize. The higher something sits, the stronger it is; anything lower is void if it conflicts with what is above.

Layer 01

Law ── the Pharmaceutical Affairs Act

The outermost fence

At the very top sits the Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices (the Pharmaceutical Affairs Act). It bans exaggerated advertising and advertising of unapproved products ── an outer frame that cannot be broken. A violation is subject to administrative action or penalties.

Layer 02

Standard ── the Standards for Fair Advertising

A yardstick that makes the law concrete

The Ministry of Health, Labour and Welfare's standard that translates the Act's advertising rules into practice. It draws the line for expressions such as "absolutely safe" or "No. 1" ── how far is permitted, and where it becomes excessive.

Layer 03

Guideline ── the Sales Information Guideline

The etiquette of the activity itself

A notice that sets out when, to whom, and on what evidence information provision activities for prescription drugs should be carried out. It covers not only the content of the material but also how it is handed over and used.

Layer 04

Internal Rules · Approved Information

On-the-ground rules per product

Each company's procedures for sales information provision, and the approved indications, efficacy, and dosage for each product. On top of obeying the higher rules, it adds further product-specific constraints.

What matters is the order. A lower layer cannot overwrite a higher one. Even if a company decides internally "this wording should pass," it will not pass if it breaches the Standards for Fair Advertising. When you give the rules to an AI, you have to teach it this up-and-down relationship as well; otherwise the AI looks only at the internal template in front of it and overlooks the higher-level regulation. Build the fences from the outermost inward. That is the starting point of the design.

02Turning the Act and the Sales Information Guideline into a "Frame" ── Teach the Prohibitions First

Now we make the outermost fence concrete. For the Act's advertising rules, pin down the exact location of the provisions first. The ban on exaggerated advertising is Article 66, the ban on advertising unapproved drugs and the like is Article 68, and the proper conduct of information provision within sales information activities is Article 68-2. Mistake the numbers and the very rule you embed in the AI is wrong, so treat this as a fixed, non-negotiable fact.

The Sales Information Guideline ── properly the "Guideline on Sales Information Provision Activities for Prescription Drugs" (notice of the Director-General of the Pharmaceutical Safety and Environmental Health Bureau, MHLW, 2018) ── is the document that sets out how this information provision activity should be conducted in the field. The key point is that it targets not only the wording of the material but the "activity" itself. It reaches into whom you may tell, on what supporting evidence, and how far.

A boundary you must not blur: What an MR (= Medical Representative), who handles information provision for prescription drugs, may deal with is strictly product information provision. Matters of transaction ── price, stock, delivery timing, ordering, discount negotiation ── are not the MR's domain. Those move between the pharmaceutical wholesaler and the hospital's purchasing department. When you have an AI write promotional copy, forbid it up front, as part of the frame, from drifting across this line into transaction-suggesting expressions like "a great deal" or "only now."

Here is one design insight. For an AI, teaching "what must not be written" is more effective than teaching "what may be written" first. What may be written is countless, product by product; what must not be written is fixed into categories by the regulation. Stand up the fence of prohibitions first, and the range the AI can generate automatically narrows toward the safe side. A fence is built not to make a path, but to keep you from falling off the cliff.

03Approved Information and Prohibited Terms ── Give It Two Dictionaries

When you bring the frame down to concrete data, what you give the AI comes down to two "dictionaries": the dictionary of approved information and the dictionary of prohibited terms. The former sets the upper bound of "you may say this much"; the latter sets the lower bound of "you must not say this."

The dictionary of approved information is a structured version, kept as-is, of each product's approved indications and efficacy, dosage and administration, warnings and contraindications. As we saw in Vol. 3, efficacy can only be spoken of within the approved scope. To keep the AI from giving in to the temptation to "widen the indication," you hand it the approved wording as the ground-truth data first, so that expressions straying from it can be rejected.

The dictionary of prohibited terms is a list of "words that are dangerous to use," derived from the regulation and the standard. Organized, it breaks down as follows.

Type of prohibited termExamples, and why they are dangerous
Superlatives · assertions"the best," "No. 1," "absolute," "completely cures" ── expressions that guarantee superiority or effect easily touch exaggerated advertising (Article 66)
Guarantees of safety"no side effects," "use with peace of mind" ── no drug is absolutely safe; these expressions paper over risk
Suggestion of the unapprovedwords that hint at unapproved indications, targets, or doses ── they step into the territory of Article 68
Inducement to transact"a great deal," "now only," "discount" ── they cross beyond information provision and bring in transaction terms an MR does not handle

These two dictionaries are not things for the AI to "sense on its own." They are things you hand it from outside as explicit data. When the approved information is revised, swap out the dictionary; when a new offending expression is found, add it to the prohibited terms. Write the rules into the code or the prompt and you end up fixing everything every time something changes. Keep them outside as dictionaries and you only have to replace the contents.

04Designing the Prompt and the Check ── Build a Two-Stage Fence

Once the dictionaries are in place, where do you make them take effect? Build the fence in two stages: the fence before generation (the prompt) and the fence after generation (the check). Either one alone leaks.

The first stage embeds the regulatory frame into the instruction given to the AI (= the prompt, the command that writes out what you want the AI to do). "You create materials for prescription drugs. The approved indications and efficacy go this far. Do not use the following prohibited terms. Do not touch transaction terms." ── you hand these frames over first, as the premise of generation. This makes dangerous copy less likely to emerge in the first place.

But the first stage alone is not enough. As we saw in Vol. 1, an AI can pretend to obey the instruction while mixing in a plausible deviation. So you place the second stage ── an automatic check after generation. You collate the produced wording against the dictionary of prohibited terms and cross-check it against the range of approved information. Here you do not rely on the AI's judgment; you cut things off with a mechanical match.

Why two stages: The first-stage prompt is a "clever but occasionally rule-breaking" fence. The second-stage check is an "inflexible but never-overlooking" fence. Cleverness and strictness are carried by different tools. Have the AI "inspect what it wrote itself" and the check goes soft with the same habits it wrote with. The entity that generates and the entity that inspects must always be separated.

This idea of "separating the maker's role from the checker's role" is the same as a founding principle of material review itself. For the same reason a creator does not approve their own material, you do not let the AI self-approve either.

05Rules Go Stale ── Designing for Update and Maintenance

This is the most overlooked point. A guardrail is not done once you build it. Rules go stale. Approved information is revised, the interpretation of the Standards for Fair Advertising is updated, and the operation of the Sales Information Guideline changes too. A frame that was correct last year is a hole this year ── that is the scariest thing.

So at the design stage you decide the maintenance owner and the procedure as well. At a minimum, make it clear whose job each of the following three is.

Keeping versions has one more meaning. When there is an audit or a challenge, you can show that "this material was reviewed under the version of the rules that was in force at that point in time." Manage the rules as an external dictionary and stamp versions. This runs directly on from the idea, touched on in Vol. 1, of keeping the provenance (traceability) of a generated output.

06The Limits of Automation ── the Fence Does Not Guarantee a "Pass"

We have described how to assemble the fences, but there is a limit that should be stated honestly. Passing the guardrail is not proof that a material is proper. The fence only drops what is "clearly no good"; it cannot play the role of choosing what is "genuinely good."

The reason is that much of the regulation is decided by context. The same word "effective" is fine if used correctly within the approved scope, and becomes exaggeration if used in a groundless setting. The dictionary of prohibited terms leans one way or the other ── either it catches the former too and rejects it, or it misses the latter. Reading context is where today's AI is at its weakest.

The right way to use the fence: If the automatic check returns a "pass," it means only "a candidate worth a human's look." The final judgment is made by a human. Conversely, whatever the check returns as a "fail" may be stopped mechanically. Cutting off is automatic; judging the pass is human ── as long as you keep this asymmetry, the AI's guardrail helps the reviewer. Break it and treat "the AI passed it, so it's proper" as the rule, and you have the most dangerous way of using it.

So making the fence too strict is also a problem. Swing too far to the safe side and correct expressions get rejected in bulk, burying people in the work of pushing back "this is a false positive." Set the height of the fence by the balance between misses (= letting a dangerous line through) and over-detection (= stopping a correct line). This is a living parameter, one you keep tuning while in operation.

07Connections to Other Chapters ── the Rules Are the Spine Running Through the Whole Set

The guardrails assembled in this volume connect to the other volumes of this series, and to the sister series, as follows. Rule design is not a standalone technique but the spine running through the whole.

Conclusion

If you are going to have an AI make materials, build the fences before it starts running. That is the core of this volume. Fences from the top down ── the Pharmaceutical Affairs Act as the outer frame, the Standards for Fair Advertising as the yardstick, the Sales Information Guideline as the etiquette, and then the approved information per product. Bring this hierarchy down into two dictionaries, approved information and prohibited terms, and make them take effect in two stages: the prompt before generation and the check after. Separate the maker's role from the checker's role. Rules go stale, so decide up front who updates them and when, and stamp versions.

But do not forget: the fence exists to keep you from falling off the cliff, not to guide you to the right answer. A human judges the pass; the machine stops only the fail. As long as you keep this asymmetry, the guardrail makes review faster and surer. Next time we move on to turning these rules into a common language for every reviewer ── how to reduce dependence on individuals.

Key Points ── Three to Take Away
  1. The rules for materials are a hierarchy in which the upper binds the lower ── Pharmaceutical Affairs Act (exaggeration Art. 66 · unapproved Art. 68 · information provision Art. 68-2) > Standards for Fair Advertising > Sales Information Guideline > internal rules · approved information. Teach the AI this up-and-down relationship too, so it does not look only at the internal template and overlook the higher-level regulation.
  2. Bring the rules down into two pieces of external data, the "dictionary of approved information" and the "dictionary of prohibited terms," and make them take effect in two stages: the prompt before generation and the automatic check after. Always separate the maker's role (the AI) from the checker's role (mechanical matching). Do not allow self-approval. Also forbid, up front as part of the frame, the line that an MR is limited to information provision and does not handle transaction terms such as price, stock, or delivery.
  3. Passing the guardrail is not proof of propriety. Much of the regulation is decided by context, which is where the AI is weak. So keep the asymmetry: cutting off is automatic, judging the pass is human. Rules go stale, so include the update trigger, the owner, and version management in the design.
Sources · References
  1. Ministry of Health, Labour and Welfare. Act on Securing Quality, Efficacy and Safety of Pharmaceuticals and Medical Devices (Pharmaceutical Affairs Act), Articles 66, 68, and 68-2. (The provisions on the ban on exaggerated advertising, the ban on advertising unapproved drugs and the like, and the proper conduct of information provision within sales information activities, respectively.)
  2. Director-General, Pharmaceutical Safety and Environmental Health Bureau, MHLW. Guideline on Sales Information Provision Activities for Prescription Drugs. Yakusei-hatsu 0925 No. 1, September 25, 2018 (applied from April 1, 2019). (The primary source defining the targets, methods, and structure of information provision activities.)
  3. Director, Compliance and Narcotics Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW. On the Revision of the Standards for Fair Advertising of Pharmaceuticals and the Like. Yakusei-kanma-hatsu 0929 No. 5, September 29, 2017. (The notice translating the Act's advertising rules into a practical standard; issued by the Director of the Compliance and Narcotics Division.)
  4. Director, Compliance and Narcotics Division, Pharmaceutical Safety and Environmental Health Bureau, MHLW. On the Commentary and Points to Note regarding the Standards for Fair Advertising of Pharmaceuticals and the Like. Yakusei-kanma-hatsu 0929 No. 6, September 29, 2017. (The interpretation of each provision of the Standards for Fair Advertising and points to note in operation.)
  5. Ministry of Health, Labour and Welfare. On the Q&A regarding the Guideline on Sales Information Provision Activities for Prescription Drugs. (Q&A on the operation of the Sales Information Guideline; concrete examples of the range and structure of information provision.)